Viridian Therapeutics, Inc\de 8-K filings

Viridian Therapeutics announced strong second quarter 2026 results, highlighted by the FDA approval and launch of Lumvoa for thyroid eye disease and robust pipeline advancements.

Viridian Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and approval of key proposals.

Viridian Therapeutics announced the successful completion of a $250 million convertible notes offering and a $117 million equity offering, bolstering its financial position for R&D and market expansion.

Viridian Therapeutics reported positive topline results from its Phase 3 REVEAL-2 trial for elegrobart in chronic thyroid eye disease, meeting primary endpoints and showing statistically significant improvements.

Viridian Therapeutics reported Q1 2026 financial results, highlighting readiness for the veligrotug launch with a PDUFA date of June 30, 2026, and positive Phase 3 data for subcutaneous elegrobart.

Viridian reported highly significant Phase 3 REVEAL-1 results for subcutaneous elegrobart in active thyroid eye disease, outlined near-term veligrotug PDUFA on June 30, 2026, and reiterated cash runway to profitability.

Viridian Therapeutics announced its fourth quarter and full year 2025 financial results, highlighting significant progress in its Thyroid Eye Disease (TED) pipeline with key regulatory and clinical milestones achieved.

Viridian Therapeutics reported strong Q3 2025 financial results, secured up to $889 million in financing, submitted its veligrotug BLA for TED, and accelerated VRDN-003 data readouts.

Viridian Therapeutics, Inc. announced a public offering of 11,425,000 common shares, expected to generate $251.35 million in gross proceeds to fund anticipated operations.

Viridian Therapeutics announced a preliminary cash, cash equivalents, and marketable securities balance of approximately $490.9 million as of September 30, 2025.

Viridian Therapeutics has secured up to $600 million in new financing through a revenue participation agreement and an amended term loan facility to advance its clinical programs.

Viridian Therapeutics reports strong Q2 2025 financial results, highlights Breakthrough Therapy Designation for veligrotug, and secures a significant Japan licensing deal, bolstering its cash position and advancing its rare disease pipeline.

Viridian Therapeutics has entered into an exclusive collaboration and license agreement with Kissei Pharmaceutical for the development and commercialization of veligrotug and VRDN-003 in Japan, including an upfront payment of $70 million and potential milestones up to $315 million.

Viridian Therapeutics, Inc. announced that its stockholders approved an amendment to its 2016 Equity Incentive Plan, increasing the shares available for issuance by 8 million, alongside the election of all director nominees and other key proposals at its 2025 Annual Meeting.

Viridian Therapeutics reports that 70% of patients treated with veligrotug in the THRIVE trial who showed a proptosis response at week 15 maintained that response at week 52.

Viridian Therapeutics remains on track with its clinical programs and anticipates a BLA submission for veligrotug in the second half of 2025, while reporting a strong cash position of $636.6 million.

Viridian Therapeutics appoints Jeff Ajer, former Chief Commercial Officer at BioMarin, to its Board of Directors to enhance commercial strategy and execution.

Viridian Therapeutics announces the appointment of Christopher Cain to its Board of Directors and the resignation of Peter Harwin, both effective March 10, 2025.

Viridian Therapeutics enters into an agreement with Jefferies LLC for a potential $300 million at-the-market offering to fund clinical development and commercialization efforts.

Viridian Therapeutics announces positive topline Phase 3 data for veligrotug in thyroid eye disease and reports a strong cash position of $717.6 million.

Viridian Therapeutics announces the appointment of Seth Harmon as its new Chief Financial Officer, effective January 1, 2025.

Viridian Therapeutics' veligrotug met all primary and secondary endpoints in a Phase 3 trial for chronic thyroid eye disease, showing significant improvements in proptosis, diplopia, and clinical activity scores.

Viridian Therapeutics announced positive topline Phase 3 results for veligrotug in active thyroid eye disease and provided updates on its broader pipeline and financial position.

Viridian Therapeutics has successfully raised approximately $258.8 million through a public offering of common and preferred stock, extending its operational runway into the second half of 2027.

Viridian Therapeutics' veligrotug (VRDN-001) met all primary and secondary endpoints in a Phase 3 trial for active thyroid eye disease, showing significant improvements in key disease indicators.

Viridian Therapeutics announced positive progress in its thyroid eye disease (TED) portfolio, including completed enrollment in a key trial and upcoming trial initiations, alongside its second quarter 2024 financial results.

Viridian Therapeutics has released an updated investor presentation highlighting progress in its Thyroid Eye Disease (TED) and FcRn inhibitor programs, with several key data readouts and regulatory submissions anticipated through 2026.

Viridian Therapeutics' stockholders approved an amendment to the 2016 Equity Incentive Plan, increasing the shares available for issuance by 2,000,000, at their 2024 Annual Meeting.

Viridian Therapeutics announced the completion of enrollment in a key clinical trial, progress in other trials, and its first quarter 2024 financial results, highlighting a strong cash position.

Viridian Therapeutics has amended its lease agreement, relocating to a new suite within its current headquarters building and extending the lease term by five years.